Overview
- A team led by researchers at the University of East Anglia reported in early September 2026 that the small molecule CADD522 improved bone volume and preserved bone microarchitecture in ovariectomized mice after eight weeks of treatment.
- The treated mice showed signs of new bone formation on blood tests and had less body fat and lower body weight than untreated controls despite similar food intake.
- CADD522 was developed to block the transcription factor RUNX2 for cancer work, and the authors suggest RUNX2 inhibition may change how bone and lipid metabolism adapt after menopause, although the exact mechanism is not yet clear.
- Short-term safety and pharmacology studies in mice, rats and dogs found oral bioavailability and tolerability, and ex vivo tests showed the drug is metabolized more slowly in human tissue than in rodents, which could affect dosing in people.
- The findings are early-stage animal results published in npj Drug Discovery and do not prove benefit or safety in humans; the authors call for more mechanistic studies and carefully designed clinical trials before any patient use can be considered.